Equities research analysts expect that Equillium, Inc. (NASDAQ:EQ) will post earnings per share (EPS) of ($0.34) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Equillium’s earnings, with estimates ranging from ($0.40) to ($0.24). Equillium reported earnings of ($0.36) per share in the same quarter last year, which would suggest a positive year over year growth rate of 5.6%. The business is scheduled to announce its next earnings results on Wednesday, March 23rd.
According to Zacks, analysts expect that Equillium will report full year earnings of ($1.33) per share for the current year, with EPS estimates ranging from ($1.40) to ($1.20). For the next financial year, analysts expect that the firm will report earnings of ($1.49) per share, with EPS estimates ranging from ($1.97) to ($1.10). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Equillium.
Equillium (NASDAQ:EQ) last announced its quarterly earnings results on Wednesday, November 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01).
NASDAQ EQ opened at $3.67 on Friday. Equillium has a 12 month low of $3.35 and a 12 month high of $11.33. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.85 and a quick ratio of 11.85. The firm has a market capitalization of $107.86 million, a PE ratio of -2.72 and a beta of 1.34. The company’s 50 day simple moving average is $4.65 and its 200 day simple moving average is $5.51.
In other Equillium news, CFO Jason A. Keyes sold 5,000 shares of the business’s stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $5.08, for a total value of $25,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 32.70% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Securities LLC bought a new stake in shares of Equillium during the third quarter worth approximately $573,000. Citadel Advisors LLC bought a new stake in shares of Equillium during the third quarter worth approximately $74,000. Geode Capital Management LLC raised its stake in shares of Equillium by 2.4% during the third quarter. Geode Capital Management LLC now owns 154,185 shares of the company’s stock worth $1,051,000 after buying an additional 3,603 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Equillium by 9.4% during the third quarter. Victory Capital Management Inc. now owns 3,170,199 shares of the company’s stock worth $21,621,000 after buying an additional 273,324 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in Equillium by 38.4% during the second quarter. Bridgeway Capital Management LLC now owns 141,200 shares of the company’s stock valued at $832,000 after purchasing an additional 39,200 shares during the period. 24.92% of the stock is owned by institutional investors.
Equillium Company Profile
Equillium, Inc engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D.
Read More: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.